Baicalein exerts antitumor effect in cervical cancer

The work verified that baicalein (BCN) inhibited the appearance and progress of cervical cancer in vitro and in vivo. MTT and CCK-8 methods were used to detect the toxicity of BCN to C33A cells and the number of C33A cells, respectively. For in vivo assays, a solid tumor model of cervical cancer and ascites tumor model was successfully established. The body weight, tumor volume and weight, survival time, and ascites volume were recorded. The anti-tumor ratio and increasing rate of life span were computed. H&E staining was performed to examine the liver tissues, kidney tissues, and tumor tissues. BCN inhibits the proliferation of human cervical cancer cell line C33A and induces apoptosis. The results from in vivo assays showed that BCN suppressed tumor growth and progression with decreased tumor volume and weight in a solid tumor model. BCN significantly induced cell apoptosis in solid tumor tissues. BCN also reduced ascites volume, prolonged survival time, and increased life extension rate in the ascites tumor model. These findings indicated that BCN exerted an antitumor effect against cervical cancer both in vitro and in vivo. According to the results, BCN might act as an important antitumor agent against cervical cancer.

Rhamnetin improves antioxidant status in the liver of Ehrlich solid tumor bearing mice

Objective: Rhamnetin, a flavanol, is in the subclasses of the flavonoids existing in plants. The antioxidant properties of several plants containing flavonoids have been extensively studied in several diseases including cancer. This study investigated the effects of rhamnetin on tumor masses, oxidant and antioxidant status in the livers of mice bearing Ehrlich solid tumor. Material and Methods: Fifty male Balb/C mice weighing 25-30 g were used in the study. Ten mice were kept for Ehrlich ascites tumor (EAT) cells production and the remaining mice were randomly assigned to four groups containing 10 mice in each as healthy control and treatments receiving 1x106 EAT cells and EAT cells plus 100 µg/kg/day or 200 µg/kg/day rhamnetin via subcutaneous route. The tumor inhibition rates of rhamnetin treatments were calculated. The livers were analyzed for malondialdehyde (MDA), superoxide dismutase (SOD) and catalase (CAT) levels. Results: Compare to tumor control, both levels of rhamnetin suppressed tumor masses throughout the experiment. The MDA levels were increased whereas SOD and CAT activities were reduced by EAT cells injection in the liver of mice. The 100 µg/kg/day rhamnetin treatment decreased MDA level but 200 µg/kg/day rhamnetin had no significant effect on increased MDA level. The reduced liver SOD (p<0.001) and CAT (p<0.01) activities were elevated by both levels of rhamnetin injection. Conclusions: The results of this study have revealed that rhamnetin suppresses tumor progression and improves antioxidant status in the livers of solid tumor-bearing mice.